Durect’s shares are crashing again.
Two years after a Novartis-partnered Phase III flop sent them into penny stock territory, Durect has failed another trial for a top candidate. This time, though, the biotech may have better fallback options.
Surging drug prices in the United States are a thorny yet key bipartisan issue as another presidential election beckons. While US President Trump struggles to make good on his promise to lower drug prices, the industry, which has long thrived in its la… […]
The applicant will be responsible for sales and business development efforts. Olink Proteomics is a rapidly growing technology company dedicated to helping…From Olink Proteomics – Thu, 02 Jan 2020 13:56:08 GMT – View all San Francisco, CA jobs […]
SOUTH SAN FRANCISCO, Calif., Jan. 2, 2020 /PRNewswire/ — ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko,… […]
Single Dose Resulted in Sustained Mean Reduction of 96% in Bleed Rates at 6e13 vg/kg Dose in Third YearCompletely Eliminated Prophylactic Factor VIII Use in 6e13 vg/kg and 4e13 vg/kg Doses2nd Publication in NEJM on Valoctocogene Roxaparvovec
SAN RAF… […]